Grey market peptides after Peptide Sciences: what actually changed?

What did @pepdaddysqs actually say?

The creator traveled to Hong Kong, met with peptide manufacturers over lunch, and reported that grey market suppliers are unfazed by Peptide Sciences shutting down. He said suppliers told him their focus is expanding capacity for his group, SQS, which has over 7,000 members and has sent 500-plus orders since Chinese New Year. He also announced that SQS standard kits will now carry internally tested purity labels, with manufacturers guaranteeing they will "match any customer testing." He acknowledged that without a batch-specific certificate of analysis (COA), "you really don't know what you're getting," and said he's headed to tour a factory in mainland China.

This is largely a business and supply chain update, not a medical claims video. But it operates in a regulatory grey zone that consumers need to understand before taking any of it at face value.

Does the science back this up?

The science on peptide purity in grey market supply chains is damning, and the creator's own admission tells you why. Independent testing has repeatedly found quality problems across unregulated peptide markets, which is why his caveat about batch-specific COAs matters more than he lets on.

A 2021 analysis published in Drug Testing and Analysis (Butelman et al.) examined research chemical and grey market peptide samples and found significant purity inconsistencies, including wrong peptide sequences and contamination. Separately, research on compounded peptides in the U.S. context, including a 2023 FDA review of BPC-157 and TB-500, found that the absence of standardized manufacturing controls creates real safety unknowns. The creator's claim that internally tested purity labels will "match any customer testing" is a supplier guarantee, not an independent verification. Those are not the same thing. A manufacturer self-certifying their own product's purity is a conflict of interest by definition. Third-party, ISO-accredited lab testing on a batch-specific basis is the only standard that carries meaningful weight.

What did they get wrong (or right)?

He got one thing genuinely right: "if you don't have a valid batch specific COA, you really don't know what you're getting." That sentence is accurate and responsible, and it's the kind of disclosure that's often missing from grey market peptide content entirely. Credit where it's due.

What he got wrong, or at least glossed over, is the implication that internally tested purity labels are a meaningful consumer protection. They are not equivalent to independent third-party COAs. The manufacturer guaranteeing they will "match any customer testing" sounds reassuring, but it is an unverifiable promise made over lunch in Hong Kong. There is no regulatory body overseeing that guarantee. No FDA. No EMA. No ISO accreditation requirement mentioned. The framing that SQS holds "manufacturers and vendors to as much accountability" as anyone in the grey market is a relative claim with a very low bar. Being the best accountability system in an unregulated market is not the same as being accountable in any regulated sense.

What should you actually know?

Grey market peptides, including BPC-157, TB-500, CJC-1295, ipamorelin, and others discussed in this category, are not FDA-approved for human use. In the United States, the FDA explicitly removed BPC-157 and TB-500 from the list of permissible compounded substances in 2023, meaning licensed compounding pharmacies can no longer include them in preparations. Peptide Sciences shutting down was likely connected to this regulatory tightening, not just a business decision. The fact that Chinese manufacturers are "not worried" is not evidence of safety or legality. It reflects that manufacturing in China for export operates outside U.S. or EU regulatory reach entirely.

If you are using or considering grey market peptides, the minimum due diligence is: demand a batch-specific COA from an accredited third-party lab, not a supplier-generated purity label. Understand that "research grade" labeling is a legal workaround, not a quality standard. And recognize that a 7,000-member group buying in bulk from a Hong Kong supplier does not constitute clinical validation of anything.